-
1
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
-
2
-
-
34547638047
-
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
-
Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
-
(2007)
Nature
, vol.448
, pp. 561-566
-
-
Soda, M.1
Choi, Y.L.2
Enomoto, M.3
Takada, S.4
Yamashita, Y.5
Ishikawa, S.6
-
3
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
Yang, C.H.4
Chu, D.T.5
Saijo, N.6
-
4
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
-
(2010)
N Engl J Med
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
Shaw, A.T.4
Solomon, B.5
Maki, R.G.6
-
5
-
-
70349336416
-
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
-
Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4247-4253
-
-
Shaw, A.T.1
Yeap, B.Y.2
Mino-Kenudson, M.3
Digumarthy, S.R.4
Costa, D.B.5
Heist, R.S.6
-
6
-
-
48249114422
-
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
-
Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14:4275-4283.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4275-4283
-
-
Koivunen, J.P.1
Mermel, C.2
Zejnullahu, K.3
Murphy, C.4
Lifshits, E.5
Holmes, A.J.6
-
7
-
-
77954399760
-
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
-
Zhang X., Zhang S., Yang X., Yang J., Zhou Q., Yin L., et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010, 9:188.
-
(2010)
Mol Cancer
, vol.9
, pp. 188
-
-
Zhang, X.1
Zhang, S.2
Yang, X.3
Yang, J.4
Zhou, Q.5
Yin, L.6
-
8
-
-
80052793410
-
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
-
Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 71:6051-6060.
-
(2011)
Cancer Res
, vol.71
, pp. 6051-6060
-
-
Sasaki, T.1
Koivunen, J.2
Ogino, A.3
Yanagita, M.4
Nikiforow, S.5
Zheng, W.6
-
9
-
-
78650950138
-
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations
-
Tiseo M., Gelsomino F., Boggiani D., Bortesi B., Bartolotti M., Bozzetti C., et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011, 71:241-243.
-
(2011)
Lung Cancer
, vol.71
, pp. 241-243
-
-
Tiseo, M.1
Gelsomino, F.2
Boggiani, D.3
Bortesi, B.4
Bartolotti, M.5
Bozzetti, C.6
-
10
-
-
78650499456
-
Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation
-
Kuo Y.W., Wu S.G., Ho C.C., Shih J.Y. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 2010, 5:2039.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 2039
-
-
Kuo, Y.W.1
Wu, S.G.2
Ho, C.C.3
Shih, J.Y.4
-
11
-
-
80054911665
-
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib
-
Popat S., Vieira de Araújo A., Min T., Swansbury J., Dainton M., Wotherspoon A., et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol 2011, 6:1962.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1962
-
-
Popat, S.1
Vieira de Araújo, A.2
Min, T.3
Swansbury, J.4
Dainton, M.5
Wotherspoon, A.6
-
12
-
-
37549050186
-
Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung
-
Kim Y.T., Kim T., Lee D.S., Park S.J., Park J., Seo S.J., et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer 2008, 59:111-118.
-
(2008)
Lung Cancer
, vol.59
, pp. 111-118
-
-
Kim, Y.T.1
Kim, T.2
Lee, D.S.3
Park, S.J.4
Park, J.5
Seo, S.J.6
-
13
-
-
77649308276
-
Gene copy number leads to shorter survival in patients with non-small cell lung cancer
-
Go H., Jeon Y.K., Park H.J., Sung S.W., Seo J.W., Chung D.H., et al. gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 2010, 5:305.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 305
-
-
Go, H.1
Jeon, Y.K.2
Park, H.J.3
Sung, S.W.4
Seo, J.W.5
Chung, D.H.6
-
14
-
-
32944468710
-
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
-
Janne P.A., Borras A.M., Kuang Y., Rogers A.M., Joshi V.A., Liyanage H., et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006, 12:751-758.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 751-758
-
-
Janne, P.A.1
Borras, A.M.2
Kuang, Y.3
Rogers, A.M.4
Joshi, V.A.5
Liyanage, H.6
-
15
-
-
0037025173
-
Addiction to oncogenes - the Achilles heal of cancer
-
Weinstein I.B. Addiction to oncogenes - the Achilles heal of cancer. Science 2002, 297:63.
-
(2002)
Science
, vol.297
, pp. 63
-
-
Weinstein, I.B.1
-
16
-
-
33746388176
-
"Oncogenic Shock": explaining oncogene addiction through differential signal attenuation
-
Sharma S.V., Fischbach M.A., Haber D.A., Settleman J. "Oncogenic Shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 2006, 12:4392s-4395s.
-
(2006)
Clin Cancer Res
, vol.12
-
-
Sharma, S.V.1
Fischbach, M.A.2
Haber, D.A.3
Settleman, J.4
-
17
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039.
-
(2007)
Science
, vol.316
, pp. 1039
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
Song, Y.4
Hyland, C.5
Park, J.O.6
-
18
-
-
52749099497
-
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
-
Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008, 9:962-972.
-
(2008)
Lancet Oncol
, vol.9
, pp. 962-972
-
-
Linardou, H.1
Dahabreh, I.J.2
Kanaloupiti, D.3
Siannis, F.4
Bafaloukos, D.5
Kosmidis, P.6
|